Collaboration Aims to Drive Commercialization of Next-Generation Therapies

In a Sep. 11, 2019 press release, TrakCel and McKesson have formed a collaboration that is aimed at accelerating commercialization of cell and gene therapies by leveraging services to enable a more efficient development pathway.

Under the terms of the collaboration, the companies will integrate TrakCel’s data tracking and personalized medicine orchestration software system and McKesson’s high-touch patient platform to provide an end-to-end solution. After the companies have developed an initial solution design, it will be offered to clients on an individual basis, depending on whether it will be beneficial.

“TrakCel and McKesson have committed to working closely with a variety of current and future clients to specifically develop tailor-made solutions,” said Ravi Nalliah, CEO of TrakCel. “This integration of solutions and expertise with McKesson will enable us to continue to meet the needs of the cell and gene therapy sector and patients as more products move towards commercialization.”  

“Precision medicine and the delivery of innovative cell and gene therapies require a personalized approach,” said Layne Martin, VP/GM, Specialty Distribution Solutions, McKesson Life Sciences. “TrakCel’s robust data tracking and verification capabilities, combined with McKesson’s industry leading 3PL, specialty pharmacy solutions and patient support capabilities, are critical to helping manufacturers safely and effectively commercialize innovative new therapies. This integrated system will help prescribers and manufacturers work together seamlessly to ensure that the right patient always receives the correct therapeutic product at the right time.”

Source: TrakCel